Physician profile
Umpai Tedrow
NPI 1578791513
$7,994.46
in general payments reported to CMS, 2019-2025
37 companies · $1,658 in 2025
The $1,658 reported for 2025 was more than what 93% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $558 · 2020: $77.70 · 2021: $734 · 2022: $1,534 · 2023: $1,758 · 2024: $1,675 · 2025: $1,658.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,091.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,090.80 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $1,255.00 | 2021-2025 | Caplyta |
| Neurocrine Biosciences, INC. | $966.47 | 2021-2025 | Ingrezza |
| Otsuka America Pharmaceutical, INC. | $887.21 | 2019-2025 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Abbvie INC. | $602.09 | 2019-2025 | Vraylar |
| Teva Pharmaceuticals USA, INC. | $519.06 | 2021-2025 | Uzedy, Austedo Xr, Austedo |
| Almatica Pharma LLC | $446.87 | 2021-2025 | Loreev Xr, Sertraline Hcl |
| Alkermes, INC. | $415.22 | 2022-2025 | Aristada, Lybalvi |
| Janssen Pharmaceuticals, INC | $364.33 | 2019-2025 | Invega Sustenna, Invega Trinza |
| Vanda Pharmaceuticals INC. | $363.65 | 2021-2025 | Fanapt, Hetlioz |
| Noven Therapeutics, LLC | $319.31 | 2021-2025 | Secuado, Xelstrym |
| Lilly USA, LLC | $229.68 | 2019-2022 | |
| Indivior INC. | $209.44 | 2022-2024 | Perseris |
| Novo Nordisk INC | $169.78 | 2019-2023 | Rybelsus, Ozempic |
| Astrazeneca Pharmaceuticals Lp | $168.10 | 2019-2020 | |
| Allergan, INC. | $153.84 | 2019 |
Show all 37 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Umpai Tedrow listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.